ArticleThe Journal of pediatrics2006
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.
Article in The Journal of pediatrics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 61 citations in OpenAlex.
- Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2007Trial
- Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation.Pediatric transplantation · 2026Article
- Biologics in renal transplantation.Pediatric nephrology (Berlin, Germany) · 2015Review
- The effects of preoperative immunosuppressive therapy on ischemia and reperfusion (I/R) injury in healthy rats.International urology and nephrology · 2014Article
- Steroid withdrawal in renal transplantation.Pediatric nephrology (Berlin, Germany) · 2013Review
- Alemtuzumab induction in pediatric kidney transplantation.Pediatric transplantation · 2013Article
- Kidney after nonrenal transplantation-the impact of alemtuzumab induction.Transplantation · 2009Article
- Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.Transplantation · 2009Article
- Post-transplant lymphoproliferative disease.Pediatric nephrology (Berlin, Germany) · 2009Article
- Mycobacterium haemophilum infection after alemtuzumab treatment.Emerging infectious diseases · 2008Article
- Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction.Transplantation · 2008Article
- Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.Transplantation · 2008Article
- Review
- Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy.Transplantation · 2007Article
- Induction therapy in pediatric renal transplant recipients: an overview.Paediatric drugs · 2007Review
- Acquired immunologic tolerance: with particular reference to transplantation.Immunologic research · 2007Article
- Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.Transplantation · 2006Article
- Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2006Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveHeavy post-transplant immunosuppression may contribute to long-term immunosuppression dependence by subverting tolerogenic mechanisms; thus, we sought to determine if this undesirable consequence could be mitigated by pretransplant lymphoid depletion and minimalistic post-transplant monotherapy. STUDY
designLymphoid depletion in 17 unselected pediatric recipients of live (n = 14) or deceased donor kidneys (n = 3) was accomplished with antithymocyte globulin (ATG) (n = 8) or alemtuzumab (n = 9). Tacrolimus was begun post-transplantation with subsequent lengthening of intervals between doses (spaced weaning). Maintenance immunosuppression, morbidity, graft function, and patient/graft survival were collated.
resultsSteroids were added temporarily to treat rejection in two patients (both ATG subgroup) or to treat hemolytic anemia in two others. After 16 to 31 months (mean 22), patient and graft survival was 100% and 94%, respectively. The only graft loss was in a nonweaned noncompliant recipient. In the other 16, serum creatinine was 0.85 +/- 0.35 mg/dL and creatinine clearance was 90.8 +/- 22.1 mL/1.73 m2. All 16 patients are on monotherapy (15 tacrolimus, one sirolimus), and 14 receive every other day or 3 times per week doses. There were no wound or other infections. Two patients developed insulin-dependent diabetes.
conclusionThe strategy of lymphoid depletion and minimum post-transplant immunosuppression appears safe and effective for pediatric kidney recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.